Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL686205 | 0.84 | CYP19A1 (0.48) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL24901084 | 0.82 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL9971266 | 0.82 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL11358004 | 0.82 | SCN9A (0.34) | CYP19A1CYP17A1NAAA | |
| SCHEMBL10257005 | 0.81 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL10188280 | 0.81 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL18467939 | 0.81 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL18648367 | 0.81 | CYP19A1 (0.46) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL686582 | 0.81 | CYP19A1 (0.40) | CYP19A1CYP17A1NAAANPSR1TSHR | |
| SCHEMBL20697766 | 0.81 | TSHR (0.40) | CYP19A1CYP17A1NPSR1TSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608313-B2 | Adamantylmethylamine derivative and use thereof as pharmaceutical | TOHOKU UNIVERSITY (JP) | 2023-03-21 | — | — | US | disclosed |
| EP-3757676-A1 | PHOTOSENSITIVE RESIN COMPOSITION, PRODUCTION METHOD THEREFOR, RESIST FILM, PATTERN FORMATION METHOD, AND METHOD FOR PRODUCING ELECTRONIC DEVICE | FUJIFILM CORPORATION (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-10450259-B2 | Compositions and methods for hydrocarbon functionalization | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170152207-A1 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION | UNITED STATES DEPARTMENT OF ENERGY | 2017-06-01 | — | — | US | disclosed |
| US-9604890-B2 | Compositions and methods for hydrocarbon functionalization | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160145188-A1 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION | UNITED STATES DEPARTMENT OF ENERGY | 2016-05-26 | — | — | US | disclosed |
| WO-2014210270-A1 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION | THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-12-31 | — | — | WO | disclosed |
| US-5015758-A | Process for the preparation of 1-adamantane derivatives | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) | 1991-05-14 | — | — | US | disclosed |
| US-4284558-A | Chemical process for fluorinating a tertiary carbon atom in the steroid nucleus | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY, INC. (US) | 1981-08-18 | — | — | US | disclosed |
| US-4036864-A | Chemical process | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145188-A1 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION | AHR, HMOX2, ALKBH3 | CYP19A1 396/4885CYP17A1 1201/4885NAAA 1361/4885 |
| US-10450259-B2 | Compositions and methods for hydrocarbon functionalization | AHR, HMOX2, HCCS | CYP19A1 224/4885CYP17A1 1070/4885NAAA 1206/4885 |
| US-20170152207-A1 | COMPOSITIONS AND METHODS FOR HYDROCARBON FUNCTIONALIZATION | AHR, HMOX2, ALKBH3 | CYP19A1 396/4885CYP17A1 1201/4885NAAA 1361/4885 |
| US-11608313-B2 | Adamantylmethylamine derivative and use thereof as pharmaceutical | APP, BACE1, PSEN1 | CYP19A1 691/4885CYP17A1 390/4885NAAA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.